Background

• The global cancer therapeutics market is expected to grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a CAGR of 7.3%. EBV associated cancer accounts for 1-2% of all cancers.

• Current treatment options for EBV-associated tumors are very limited with remarkable unwanted off-target toxicities

Technology Overview

The exosomes demonstrate an EBV-associated tumor specific tropism, ability to distinguish normal and infected B cells and capacity to trigger both tumor cell apoptosis and stimulate anti-tumor T cell activities.

Figure 1. Graph showing % apoptosis in autologous normal B cells and EBV-LCL after exosome treatment.

Figure 2. Graph showing % tumor incidence and % survival after exosome treatment.

Stage of Development

Verified in EBV-associated B-cell lymphoma model

• Potential to be the first exosome therapy for the treatment of EBV-associated cancer
• Superiority over both conventional treatments, novel cell based treatments and other immune cell derived exosomes
• Table 1

Novel therapeutic for the treatment of EBV associated cancers

Patents

• US provisional patent application No. 62916430

IP Status

• Patent application submitted